TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06494761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: repaglinide
Study: NCT05899959

Intervention type: DEVICE
Intervention: Corsano CardioWatch 287-2
Description: Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.

Intervention type: DEVICE
Intervention: Corsano CardioWatch 287-2
Description: Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
Study: NCT06147869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phonophoresis
Description: Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
Study: NCT06276348

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: Standard diagnostic whole genome sequencing will be performed.
Study: NCT04517903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye rubbing questionnaire
Description: eye rubbing questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye rubbing questionnaire
Description: eye rubbing questionnaire
Study: NCT06276348

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BeginNGS test
Description: Genomic sequencing that screens for 434 genetic diseases.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES
Description: Whole exome sequencing will be performed.
Study: NCT05962138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy for Insomnia
Description: 6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
Study: NCT04832854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT06169761

Intervention type: OTHER
Intervention: Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea
Description: The following items will be assessed:~1. Risk for sleep apnea, through the STOP-BANG Questionnaire.~2. Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~3. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~4. Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~5. Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~6. Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~7. Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements.
Study: NCT04848207

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital impression technique
Description: 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.

Intervention type: OTHER
Group type: OTHER
Intervention: Open tray impression technique
Description: Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material.
Study: NCT04832854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
Study: NCT04842019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Study: NCT04832854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
Study: NCT05773352

Intervention type: DEVICE
Intervention: Tornier Perform® Humeral System - Fracture
Description: A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.
Study: NCT04853381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment (low FODMAP)
Description: The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment (gluten free)
Description: The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment (low FODMAP+gluten free)
Description: The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment (Traditional diet recommendations)
Description: The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
Study: NCT05616806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iENDURE
Description: Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills).
Study: NCT04630639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparkle
Description: The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
Study: NCT05797480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Dry needling
Description: Real dry needling will be applied to the pelvic floor, hip and lower back muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non penetrating dry needling
Description: Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
Study: NCT06246591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy (Group A)
Description: Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
Study: NCT06497634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 PP
Description: Spinal anesthesia will be performed in sitting position, with 25 G pencil point needle (Whitacre -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 Q
Description: Spinal anesthesia will be performed in sitting position, with 25 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 27 Q
Description: Spinal anesthesia will be performed in sitting position, with 27 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optic Nerve Sheath Measurement
Description: Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.
Study: NCT06246591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy (Group B)
Description: Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
Study: NCT06385964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4597
Description: SHR-4597 by dry powder inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by dry powder inhalation
Study: NCT05536960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate PET/CT
Description: One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
Study: NCT04881188

Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
Study: NCT05991362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312 100 mg
Description: Participants receive single dose of GFH312 100 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312 200 mg
Description: Participants receive single dose of GFH312 200 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312 120mg
Description: Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo matching with GFH312
Study: NCT05662605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-PPMA
Description: W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot.
Study: NCT06468904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical stabilization exercises and integrated neuromuscular technique.
Description: Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical stabilization exercises and integrated neuromuscular technique.
Description: Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain.
Study: NCT06497634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optic Nerve Sheath Measurement
Description: Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optic Nerve Sheath Measurement
Description: Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.
Study: NCT05090397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
Study: NCT06460012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STELLA-R Curriculum
Description: The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STELLA-R Curriculum
Description: The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.
Study: NCT06380387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal
Study: NCT04476277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin label
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin label
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin label
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin label
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
Study: NCT06460012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unrestricted Access
Description: Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.
Study: NCT05090397

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham Transcranial Direct Current Stimulation